Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil

AIDS Research and Human Retroviruses

Volumn 26, Issue 1, 2010, Pages 105-107

  Arruda, Liã Bárbara ^a   Fonseca, Luiz Augusto M ^a   Duarte, Alberto J S ^a   Casseb, Jorge ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; RALTEGRAVIR;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BRAZIL; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STRUCTURAL GENE;

EID: 76449113233     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0179     Document Type: Article

References (15)

1. Malet I, Soulie C, Tchertanov L, et al.: Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol 2008;80:754-761.
2. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, and Perno CF: Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11:17-29.
3. Van Laethem K, Schrooten Y, Covens K, et al.: A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods 2008;153: 176-181.
4. Katlama C and Murphy R: Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. Ther Clin Risk Manag 2009;5: 331-340.
5. Loizidou EZ, Kousiappa I, Zeinalipour-Yazdi CD, Van de Vijver DA, and Kostrikis LG: Implications of HIV-1M group polymorphisms on integrase inhibitor efficacy and resistance: Genetic and structural in silico analyses. Biochemistry 2009;48:4-6.
6. Herring BL, Cunningham AL, and Dwyer DE: Potential drug resistance polymorphisms in the integrase gene of HIV type 1 subtype A. AIDS Res Hum Retroviruses 2004;20: 1010-1014.
7. Fikkert V, Van Maele B, Vercammen J, et al.: Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003;77:11459-11470.
8. de Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-3800.
9. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, and Shafer RW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31:298-303.
10. Rhee SY, Liu TF, Kiuchi M, et al.: Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors. Retrovirology 2008;5:74.
11. Passaes CB, Guimaraes ML, Fernandez SL, et al.: Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr 2009;51:7-12.
12. Myers RE and Pillay D: Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol 2008;82:9228-9235.
13. Eshleman SH, Hudelson SE, Smith P, et al.: Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses 2009;25:343-345.
14. Charpentier C, Karmochkine M, Laureillard D, et al.: Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008;9:765-770.
15. Konsavage WM Jr, Sudol M, and Katzman M: Effects of varying the spacing within the D,D-35-E motif in the catalytic region of retroviral integrase. Virology 2008;379:223-233.